<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recurrent fetal losses indicate screening for <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo>, especially after the third consecutive fetal loss, or when they occur after 12 weeks gestation or when the mother presents with <z:mp ids='MP_0005048'>thrombosis</z:mp> or other ailments of <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Fetal loss may be caused by thromboses of placental vasculature </plain></SENT>
<SENT sid="2" pm="."><plain>There is no agreement concerning the mechanism of thromboses: protein C pathway and/or annexin V are the best candidates </plain></SENT>
<SENT sid="3" pm="."><plain>When fetal loss occurs early during gestation, murine models suggest that <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> can also act on trophoblasts by inhibiting syncytia formation </plain></SENT>
<SENT sid="4" pm="."><plain>Among the high risk patients with more than two fetal losses, an association of aspirin and <z:chebi fb="5" ids="28304">heparin</z:chebi> given early during gestation is successful in 70-80% of cases </plain></SENT>
</text></document>